Clinical trials: Vaccine Prophylaxis

Meningococcal Disease, Meningococcal Meningitis

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

• Completed
• Age: 12 to 23 months
• Phase 2
• Results posted

The study was to evaluate the safety and and immune response of each of three lots of Novartis Meningococcal C Conjugate Vaccine (MenC-CRM Liquid) when administered to Healthy Toddlers.

Trial name

NCT01434680

Testing

MenC-CRM LIQ, MenC-CRM ROS, MenC-CRM EMV

Where

11 sites in Poland

Volunteers

992 people, healthy volunteers welcome

Sponsor

Novartis